Treatment of neurological injury by administration of human umbilical cord tissue-derived cells

• US 9,592,258 B2
• Filed: 05/06/2015
• Issued: 03/14/2017
• Est. Priority Date: 06/27/2003
• Status: Active Grant

• Current Assignee: Depuy Synthes Products Incorporated (Johnson & Johnson)
• Original Assignee: Depuy Synthes Products Incorporated (Johnson & Johnson)
• Inventors: Seyda, Agnieszka, Gosiewska, Anna
• Primary Examiner(s): BORGEEST, CHRISTINA M
• Application Number:
  US14/705,680
• Publication Number:
  US 20150231185A1
• Time in Patent Office: 678 Days
• Field of Search: None
• US Class Current: 1/1
• CPC Class Codes: A61K 35/12 Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells vaccines or medicinal preparations containing antigens or antibodies A61K39/00
• CPC Class Codes: A61K 35/30 Nerves; Brain; Eyes; Corneal cells; Cerebrospinal fluid; Neuronal stem cells; Neuronal precursor cells; Glial cells; Oligodendrocytes; Schwann cells; Astroglia; Astrocytes; Choroid plexus; Spinal cord tissue
• CPC Class Codes: A61K 35/51 Umbilical cord; Umbilical cord blood; Umbilical stem cells
• CPC Class Codes: A61K 35/545 Embryonic stem cells; Pluripotent stem cells; Induced pluripotent stem cells; Uncharacterised stem cells
• CPC Class Codes: A61K 45/06 Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
• CPC Class Codes: C12N 5/0605 Cells from extra-embryonic tissues, e.g. placenta, amnion, yolk sac, Wharton's jelly
• CPC Class Codes: C12N 5/0668 Mesenchymal stem cells from other natural sources
• CPC Class Codes: C12N 5/0682 Cells of the female genital tract, e.g. endometrium; Non-germinal cells from ovaries, e.g. ovarian follicle cells oocytes C12N5/0609

Abstract

Methods, pharmaceutical compositions and kits for regenerating or repairing neural tissue, decreasing apoptosis and improving neurological function following injury using human umbilical cord tissue-derived cells are disclosed.

Claims

1. A method of treating a patient having a neurological injury comprising administering to the patient isolated umbilical cord tissue-derived cells in an amount effective to treat the neurological injury, wherein the neurological injury is cerebral hemorrhage, cerebral ischemia or traumatic brain injury, and wherein the umbilical cord tissue-derived cells are derived from human umbilical cord tissue substantially free of blood, are capable of self-renewal and expansion in culture, have the potential to differentiate into cells of at least a neural phenotype, and do not express CD117.

2. The method of claim 1, wherein the cells are administered with at least one other cell type.

3. The method of claim 2, wherein the other cell type is an astrocyte, oligodendrocyte, neuron, neural progenitor, neural stem cell or other multipotent or pluripotent stem cell.

4. The method of claim 1, wherein the umbilical cord tissue-derived cells are administered at a pre-determined site in the central nervous system of the patient.

5. The method of claim 1, wherein the umbilical cord tissue-derived cells are administered by injection or infusion.

6. The method of claim 1, wherein the umbilical cord tissue-derived cells further express CD10, CD13, CD44, CD73, CD90, PDGFr-alpha and HLA-A, B, C.

7. The method of claim 1, wherein the umbilical cord tissue-derived cells further do not express CD31, CD34, CD45, CD141 and HLA-DR, DP, DQ.

8. The method of claim 1, wherein the neurological injury is cerebral hemorrhage.

9. The method of claim 1, wherein the neurological injury is cerebral ischemia.

10. The method of claim 1, wherein the neurological injury is traumatic brain injury.

11. A method of stimulating regeneration capacity of a subventricular zone of a patient following traumatic brain injury comprising administering to the patient isolated umbilical cord tissue-derived cells in an amount effective to increase neurogenesis, angiogenesis, or synaptogenesis, wherein the umbilical cord tissue-derived cells are derived from human umbilical cord tissue substantially free of blood, are capable of self-renewal and expansion in culture, have the potential to differentiate into cells of at least a neural phenotype, and do not express CD117.

12. The method of claim 11, wherein the umbilical cord tissue-derived cells are administered with at least one other cell type.

13. The method of claim 12, wherein the other cell type is an astrocyte, oligodendrocyte, neuron, neural progenitor, neural stem cell or other multipotent or pluripotent stem cell.

14. The method of claim 11, wherein the cells are administered at a pre-determined site in the central nervous system of the patient.

15. The method of claim 11, wherein the cells are administered by injection or infusion.

16. The method of claim 11, wherein the umbilical cord tissue-derived cells further express CD10, CD13, CD44, CD73, CD90, PDGFr-alpha and HLA-A, B, C.

17. The method of claim 11, wherein the umbilical cord tissue-derived cells further do not express CD31, CD34, CD45, CD141 and HLA-DR, DP, DQ.